Omega-3 (EPA/DHA)

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the two long-chain marine omega-3 fatty acids that account for the cardiovascular, brain-health, and now biological-aging signals in this category. ALA (alpha-linolenic acid) — the plant omega-3 in flaxseed, chia, and walnuts — converts to EPA/DHA poorly in humans (typically under 10%, with negligible yield of DHA) and is not a reliable substitute. The most useful framing: if your dietary EPA+DHA intake is adequate, supplementation is unnecessary; if it isn't, supplementation closes a measurable physiological gap that can be tracked on a single blood test.

What the evidence says

Weak-to-Moderate — for preventing heart attacks and cardiovascular death. Broad low-dose supplementation is largely neutral (Cochrane, VITAL, ASCEND); the one clearly positive high-dose trial (REDUCE-IT, EPA-only) is partly confounded by its placebo, and the matched EPA+DHA trial (STRENGTH) was null.

Moderate (as association), Weak (as causal claim) — for lower all-cause mortality tied to a higher omega-3 index. The signal is consistent across large cohorts but observational; the randomized mortality data are essentially neutral.

Weak — for slower biological aging. One post-hoc trial readout (DO-HEALTH) slowed methylation "aging clocks" modestly, but these are surrogate markers, not hard outcomes.

Moderate — for lowering triglycerides. Reliable and dose-dependent, the best-established pharmacological effect in the category.

Caution — for atrial fibrillation and bleeding at high doses. A small, dose-dependent excess of atrial fibrillation is concentrated at 4 g/day but persists modestly even at ≤1 g/day.

Two parallel stories

The literature now runs on two parallel tracks that need to be read together:

• The cardiovascular trial track. Large randomized trials at gram-level doses, looking at heart attacks, strokes, and cardiovascular death. The results here are mixed and have a real safety signal at the top of the dose range.
• The biomarker / longevity track. Observational cohorts and a handful of newer trials anchored on the omega-3 index (the EPA+DHA percentage of red-blood-cell membranes), and on epigenetic age. The signal here is more uniformly positive and dose-responsive — but the outcomes are softer (all-cause mortality, biological-age clocks) than hard events.

Almost all of the practical guidance below sits at the intersection of the two: enough EPA+DHA to put your omega-3 index in the protective range, not so much that you cross into the arrhythmia signal seen in high-dose pharmacological trials.

The cardiovascular trial puzzle

Start with the baseline the big syntheses establish, because it anchors everything that follows. The largest one — ^[1], 86 RCTs and 162,796 participants — found that increasing long-chain omega-3 has little or no effect on all-cause mortality: a 3% difference well within the range expected from chance (relative risk 0.97, 95% confidence interval 0.93–1.01; high-certainty). That bracketed range is where the true effect most plausibly lies; because it crosses 1.0, the result is compatible with no effect. Cardiovascular events told the same story — about 4% lower, but still compatible with no effect (RR 0.96, 0.92–1.01) — though omega-3 reliably lowered triglycerides and modestly lowered HDL ("good") cholesterol. A more optimistic counterweight, ^[2] (13 RCTs, 127,477 participants), found small but real reductions — about 8% each — in myocardial infarction (MI, or heart attack; RR 0.92, 0.86–0.99) and coronary death (RR 0.92, 0.86–0.98), but not stroke, with a dose-response hinting at benefit above the ~840 mg/day used in most trials. So the honest starting point for hard endpoints is neutral-to-modest, and the positive longevity framing below has to be read against it. For the dietary side of this story — fish intake, fat type, and the seed-oil debate — see Dietary fats.

Against that baseline sits a puzzle at the top of the dose range. The trial that put high-dose EPA back on the map: ^[3]. Icosapent ethyl (purified EPA, 4 g/day) cut major cardiovascular events by 25% over five years on top of optimal statin therapy. The absolute risk reduction was clinically meaningful — about 4–5 events prevented per 100 high-risk patients treated.

But STRENGTH, a similar trial using a mixed EPA+DHA formulation (carboxylic-acid form, 4 g/day), was null for cardiovascular events.^[4] Two big differences may explain the discrepancy:

• The molecule. Pure EPA versus an EPA+DHA mix. Some research suggests DHA may partly offset EPA's anti-inflammatory and membrane-stabilising effects.
• The placebo. REDUCE-IT used mineral oil, which raised LDL ("bad") cholesterol (~10%) and high-sensitivity C-reactive protein (hsCRP, an inflammation marker; ~32%) in the control group — possibly flattering the active drug by comparison. STRENGTH used corn oil, which is more biologically inert. The counterpoint: in the ^[5], regulators estimated only ~3% of the net clinical benefit was attributable to mineral oil's adverse biomarker effects. The controversy is genuine but unresolved — the placebo does not appear to explain the whole result.

The lower-dose primary-prevention trials round out the pattern. ^[6] (25,871 adults, 840 mg/day) was null on its primary composite — an 8% difference compatible with chance (hazard ratio 0.92, 0.80–1.06); the roughly 28%-lower heart-attack rate (HR 0.72, 0.59–0.90) and the benefit in low-fish-intake participants were secondary/exploratory findings, not headline results. ^[7] (15,480 people with diabetes, 1 g/day) was null for serious vascular events (8.9% vs 9.2%). ^[8] (1,027 elderly post-MI patients, 1.8 g/day vs corn oil) was null and showed a non-significant rise in new-onset atrial fibrillation.

The honest read: low-dose supplementation in unselected populations is largely neutral for hard endpoints (Cochrane, ASCEND, VITAL primary); the one clearly positive high-dose trial (REDUCE-IT, EPA-only) is partly confounded by its placebo; mixed high-dose EPA+DHA (STRENGTH, OMEMI) is null. For a healthy midlife adult: regular dietary EPA+DHA is well-supported; low-to-moderate supplemental doses are reasonable if you don't eat fish; very high doses are a prescription-territory decision.

The longevity and biological-aging signal

The newer and arguably more interesting evidence comes from biomarker cohorts and from epigenetic-age trials.

In long-running prospective cohorts, adults with an omega-3 index above roughly 6.8% have lower all-cause mortality than those below it, with the pooled estimate landing at 15–20% relative risk reduction across consortia of more than 40,000 individuals.^[9] The Framingham cohort puts the inflection near the same point — the highest quintile (>6.8%) had ~34% lower all-cause mortality than the lowest (<4.2%).^[10] The mortality signal is most consistent for cardiovascular death but extends to cancer and non-cardiovascular causes in pooled analyses. The dose-response is non-linear for EPA (largest gain in moving from deficient to sufficient, then plateaus) and more linear for DHA.

Two caveats keep this honest. These are observational associations, and fish-eaters are systematically healthier — residual confounding is the central limitation, and it cuts hard given that the randomized mortality data are essentially neutral (VITAL all-cause death HR 1.02; Cochrane little or no effect). And the omega-3 index itself is promoted heavily by a commercial testing company whose founder co-authors much of this literature, so the specific ">8% target" should be read as a cardioprotective goal, not a longevity threshold the hard-outcome data require.

The readout that elevated omega-3 from "cardiovascular nutrient" to "candidate longevity intervention" is the ^[11] (Bischoff-Ferrari et al., Nature Aging 2025). One gram per day of algal-derived omega-3 (330 mg EPA + 660 mg DHA) slowed several next-generation methylation clocks — PhenoAge, GrimAge2, and DunedinPACE — by the equivalent of roughly three to four months of biological age over three years. DunedinPACE, which estimates the current rate of aging rather than cumulative age, slowed by about 1%. The effect was additive with vitamin D and a light home-exercise program, though that additivity appeared only on PhenoAge, not GrimAge2 or DunedinPACE; first-generation clocks (Horvath, Hannum) were unaffected.

A few honest caveats — and they matter here:

• This is a post-hoc analysis of a subset (777 of 2,157 participants), and the main DO-HEALTH trial actually missed all six of its pre-registered primary endpoints (blood pressure, non-vertebral fractures, physical function, cognition, infection rate). The clock benefit is an exploratory readout, not a headline result, and the standardized effects are small (d ≈ 0.16–0.32). DunedinPACE slowed ~1%, versus 2–3% in the CALERIE caloric-restriction trial.
• The clocks are surrogate biomarkers of biological age, not hard outcomes. They predict mortality and disease in cohorts, but a slowed clock in a three-year trial is not the same as a longer life.
• The participants were over 70 — older than the typical longevity-curious 40-something — and most had baseline omega-3 indices below the protective range, leaving more room to improve.
• The clock-slowing dose (1 g/day of EPA+DHA) is well below the high-dose cardiovascular-trial range. The longevity signal does not require — and probably does not benefit from — pushing the dose to 4 g/day.

Mechanistically the case is coherent: EPA and DHA integrate into cell membranes, dampen the chronic low-grade inflammation of aging, shift lipid mediators away from pro-inflammatory prostaglandins toward specialized pro-resolving mediators (resolvins, protectins, maresins), and modulate the same nutrient-sensing and cellular-recycling pathways (the AMPK energy sensor, the SIRT1 and mTOR growth-and-repair switches, and autophagy) targeted by caloric restriction and rapamycin. None of that proves causality on its own, but it makes the clock data less surprising.

Test: the omega-3 index

The most useful single lab in this space is the omega-3 index — the percentage of EPA + DHA in red blood cell membranes:

The 8% threshold corresponds roughly to the upper-quintile cardioprotective range in pooled cohort data; the ~7% threshold marks where most longevity cohort signals start to appear. Roughly 1–2 g/day of combined EPA+DHA over 4–6 months brings most adults into the 8–12% range. People who eat fatty fish two to three times weekly often reach it without supplementation. Athletes and habitual non-fish-eaters routinely test in the 4–5% range — i.e. the bottom of the risk-elevated band — even when they consider their diets healthy. A cross-sectional analysis of collegiate athletes found a mean omega-3 index of 4.6%,^[12] and the International Society of Sports Nutrition (ISSN) position stand reports a mean of 4.4% across 404 collegiate football players, not one of whom reached 8%.^[13]

The omega-6 to omega-3 ratio

A second framing worth knowing, even though it's less actionable than the omega-3 index itself: the ratio of plasma omega-6 to omega-3 polyunsaturated fats. In a UK Biobank analysis of around 85,000 adults followed for an average of 13 years, the highest-ratio quintile carried roughly 26% higher all-cause mortality, 31% higher cardiovascular mortality, and 14% higher cancer mortality than the lowest-ratio quintile.^[14] Modern Western diets frequently sit at 15:1 or higher, against an evolutionary baseline closer to 1:1 to 5:1.

The practical implication is not to chase a target ratio — that's hard to measure cleanly outside of research labs, and the absolute omega-3 level seems to do most of the work. It is to recognize that raising EPA+DHA is the easier lever than cutting omega-6: seed oils, processed snack foods, and most restaurant cooking deliver large omega-6 loads passively. Adding fish or a supplement shifts the ratio in the right direction without requiring a dietary overhaul.

Brain, mood, and cognition

DHA is the dominant structural fatty acid in the brain; EPA is the active mood-and-inflammation lever. The clinical literature reflects that split.

In broad trials of cognitively healthy older adults, omega-3 supplementation has not moved global cognition reliably. A 2025 systematic review of 19 randomized trials in cognitively unimpaired older adults found no overall effect on global cognition.^[15] The trials are heterogeneous (doses, EPA:DHA ratios, durations, baseline status), and the broad-population effect is consistent with a small, hard-to-detect signal in the average healthy adult.

The picture changes in genetically at-risk subgroups. In the ALFA cohort of middle-aged adults with Alzheimer's risk factors (including carriers of APOE-ε4, the most common inherited risk gene for Alzheimer's), higher red-blood-cell DHA was linked to slower cognitive decline on a sensitive composite score over multi-year follow-up. EPA showed no equivalent signal in that cohort — consistent with DHA acting structurally in the neuronal membrane before symptomatic disease.^[16] This is 323 cognitively unimpaired middle-aged adults followed for three years — an observational association within a single at-risk cohort, not a trial.

For major depressive disorder, supplementation works only when the formulation is heavily EPA-weighted. Meta-analyses converge on a required EPA:DHA ratio of at least 1.5:1, and the strongest signal — in patients with elevated inflammatory markers — has come from ratios closer to 4:1 at total doses above 1 g/day. Mood depression is one of the few clinical indications where the choice of EPA:DHA ratio meaningfully changes the outcome; standard generic fish oils are not the right format.

Practical dosing

• Two or more servings of fatty fish per week (salmon, sardines, mackerel, herring, trout) — supplementation is unnecessary.
• No fish in your diet: 1–2 g/day combined EPA+DHA. This is the band that lifts the omega-3 index into the protective range, matches the DO-HEALTH clock-slowing intervention, and stays below the dose at which arrhythmia signals emerge.
• Athletes and heavy training loads: 2–3 g/day during high-volume blocks. The 2025 ISSN position stand concluded that athletes are at elevated risk of omega-3 insufficiency, that supplementation may attenuate indirect markers of muscle damage and subjective soreness, and that it can favourably shift immune-cell and cytokine responses (a reproducible drop in tumour necrosis factor-α (TNF-α), an inflammatory signalling protein, at roughly 2.4 g EPA + 1.2 g DHA per day over four weeks or more). It stops short of naming a single dose — trials span 0.9–6.3 g/day — but estimates that about 1.4 g/day of extra EPA+DHA is what it takes to lift a typical athlete's omega-3 index to 8%.^[17]
• Elevated triglycerides or established cardiovascular disease: higher doses (2–4 g/day combined, or — with a prescriber — icosapent ethyl 4 g/day) may be appropriate. The ^[18] concluded prescription omega-3 at 4 g/day lowers triglycerides by 20–30%, scaling with baseline level.
• Vegetarians and vegans: algae-derived oils provide DHA and increasingly EPA. Pharmacokinetic trials show algal oil non-inferior to fish oil for raising plasma and red-cell omega-3 levels.^[19] Microalgae are also the original biological source — fish accumulate EPA and DHA only by eating algae.

Regulatory ceilings are broadly aligned: the European Food Safety Authority concluded long-term combined EPA+DHA up to 5 g/day is safe for healthy adults, and the US FDA broadly agrees, with a 2 g/day cap on over-the-counter supplement label recommendations.

Form, sourcing, and oxidation

The product-quality question is, for most consumers, where omega-3 supplementation actually goes wrong. Three issues stack: the chemical form, the source, and oxidation.

Form

For most healthy adults, a third-party-tested rTG or ethyl ester product taken with food is adequate. The cost difference between rTG and ethyl ester is usually 2–3×; the absorption difference, with meals, is small.

Sourcing

Wild-caught small forage fish (sardines, anchovies, herring, mackerel) remain the highest-density, lowest-contaminant dietary source. Farmed Atlantic salmon was historically a comparable source but its EPA+DHA content has fallen substantially since the mid-2000s as aquaculture feeds have shifted toward cheaper terrestrial plant oils. Algal oil supplements deliver the same EPA and DHA molecules and bypass both the contaminant and sustainability concerns; recent randomized comparisons find them non-inferior to fish oil for raising blood omega-3 levels.^[20]

Oxidation and freshness

The same carbon-carbon double bonds that make EPA and DHA biologically active also make them chemically fragile. Heat, light, and ambient oxygen during manufacture, transport, and storage produce peroxides and secondary aldehydes that the industry summarizes as the TOTOX (total oxidation) value. An independent analysis of 171 North American over-the-counter omega-3 products found roughly half exceeded the voluntary oxidation thresholds set by the American Oil Chemists' Society (AOCS), with flavored and chewable formulations the worst offenders.^[21]

Rancid omega-3 doesn't just lose efficacy; it delivers a load of reactive lipid peroxidation products into the GI tract, plausibly counteracting the anti-inflammatory effect the supplement was supposed to produce.

Practical filters:

• Look for an IFOS (International Fish Oil Standards), Labdoor, USP (U.S. Pharmacopeia), or NSF mark on the bottle. IFOS specifically publishes TOTOX numbers and heavy-metal panels per batch.
• Check for a freshness signal on the certificate of analysis (TOTOX, peroxide value, anisidine value).
• Refrigerate after opening and finish the bottle within a few months.
• Trust your nose. A high-quality oil smells nearly neutral. Strong fishy odour or post-dose fishy reflux is the sensory signature of advanced oxidation, not of "real" fish oil.

The atrial fibrillation paradox

This deserves its own section because two genuinely contradictory-looking lines of evidence coexist.

The trial signal. Several high-dose randomized trials of purified or synthetic omega-3 (mostly ethyl ester, mostly at 1–4 g/day, in older patients with established cardiovascular disease) showed a small but real increase in new-onset atrial fibrillation. A pooled analysis of 7 cardiovascular-outcome trials in 81,210 patients found about a 25% higher rate of new atrial fibrillation versus placebo (hazard ratio 1.25, 95% CI 1.07–1.46), and the excess was clearly dose-dependent — roughly 49% higher above 1 g/day (HR 1.49, 1.04–2.15) versus about 12% higher at ≤1 g/day (HR 1.12, 1.03–1.22), with each additional gram per day adding ~11% (HR 1.11).^[22] Both REDUCE-IT and STRENGTH contributed at the 4 g/day dose.

The biomarker signal — pointing the other way. When the question is asked using physiological status rather than pharmacological dose, the relationship flips. In the UK Biobank, higher plasma omega-3 was associated with an ~11% lower incidence of new AFib per step up in blood level (hazard ratio ~0.89 per interquartile-range increase), and self-reported over-the-counter fish-oil use in the general population showed no increased AFib risk after adjustment for age and other confounders.^[23]

The reconciliation most consistent with the data: chronic, moderate dietary or supplemental intake that gradually raises membrane EPA/DHA appears to be protective against atrial remodelling. Acute high-dose loading in older, already-diseased patients may transiently destabilize cardiac membrane electrophysiology and tip a small number of susceptible patients into atrial fibrillation. The relevant clinical lesson is dose discipline: the excess is small and concentrated at high doses, but a modest signal persists even at ≤1 g/day (HR 1.12). Routine 1–2 g/day is associated with the protective biomarker signal; 4 g/day is prescription-territory and carries a clearer AFib excess that has to be weighed against the (substantial) cardiovascular event reduction it also produces.

Cautions

• Atrial fibrillation signal at high doses (Caution). As above — concentrated at 4 g/day in older diseased populations, but a modest excess (HR 1.12) persists even at ≤1 g/day.
• Bleeding. High-dose omega-3 lengthens bleeding time modestly. Surgical guidelines vary; many clinicians advise stopping for about a week before elective surgery.
• Drug interactions. Anticoagulants and antiplatelet drugs can have additive bleeding effects with very high omega-3 doses.
• Pregnancy / lactation. DHA is important — the requirement actually rises — but choose products with verified low contaminant panels.

What to skip

• ALA-only supplements (flaxseed oil, chia oil) — ALA converts to EPA/DHA at single-digit-percent rates and yields negligible DHA. Useful as food, not as a substitute for marine omega-3.
• Generic "fish oil" without a third-party oxidation certificate. Rancid product is common, especially on unrefrigerated retail shelves, and undoes most of the point of supplementing.
• Krill oil at premium prices — the absorption advantage doesn't justify the per-gram cost of EPA+DHA delivered for most people.
• Flavoured, gummy, or chewable omega-3 for adults — the freshness data on these formats is consistently the worst, and the per-capsule EPA+DHA load is low.

Further reading

• Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). NEJM 2019.^[24]
• Nicholls SJ et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events (STRENGTH). JAMA 2020.^[25]
• Manson JE et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL). NEJM 2019.^[26]
• Harris WS et al. Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies (FORCE consortium). Nature Communications 2021.^[27]
• Bischoff-Ferrari HA et al. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks (DO-HEALTH). Nature Aging 2025.^[28]
• Abdelhamid AS et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease (Cochrane). Cochrane Database Syst Rev 2020.^[29]
• ASCEND Study Collaborative Group. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. NEJM 2018.^[30]
• Gencer B et al. Effect of Long-Term Marine n-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in RCTs of Cardiovascular Outcomes. Circulation 2021.^[31]
• Skulas-Ray AC et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the AHA. Circulation 2019.^[32]
• O'Keefe E et al. Associations Between Plasma Omega-3 and Fish Oil Use With Risk of Atrial Fibrillation in the UK Biobank. J Am Heart Assoc 2025.^[33]
• Jackowski SA et al. Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety. J Nutr Sci 2015.^[34]
• Jäger R et al. International Society of Sports Nutrition Position Stand: Long-Chain Omega-3 Polyunsaturated Fatty Acids. J Int Soc Sports Nutr 2025.^[35]
• Lázaro I et al. Red blood cell ω-3 status and longitudinal cognition in individuals at risk of Alzheimer disease (ALFA+). J Nutr 2025.^[36]
• Heileson JL et al. A Cross-Sectional Analysis of Whole Blood Long-Chain ω-3 Polyunsaturated Fatty Acids and Its Relationship with Dietary Intake, Body Composition, and Measures of Strength and Power in Collegiate Athletes. J Am Nutr Assoc 2023.^[37]

---